Anti- factor IIa (FIIa) heparin assay for patients on direct factor Xa (FXa) inhibitors
dc.contributor.author | Stuart, Morgan | |
dc.contributor.author | Johnson, Linda | |
dc.contributor.author | Hanigan, Sarah | |
dc.contributor.author | Pipe, Steven W. | |
dc.contributor.author | Li, Shih‐hon | |
dc.date.accessioned | 2020-08-10T20:53:12Z | |
dc.date.available | WITHHELD_12_MONTHS | |
dc.date.available | 2020-08-10T20:53:12Z | |
dc.date.issued | 2020-07 | |
dc.identifier.citation | Stuart, Morgan; Johnson, Linda; Hanigan, Sarah; Pipe, Steven W.; Li, Shih‐hon (2020). "Anti- factor IIa (FIIa) heparin assay for patients on direct factor Xa (FXa) inhibitors." Journal of Thrombosis and Haemostasis 18(7): 1653-1660. | |
dc.identifier.issn | 1538-7933 | |
dc.identifier.issn | 1538-7836 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/156142 | |
dc.description.abstract | BackgroundDirect factor Xa (FXa) inhibitors are increasingly prescribed for outpatients, and those transitioning to unfractionated heparin (UFH) for hospital admission are monitored via an anti- FXa assay. Because of assay interference, UFH results would often be critically elevated, confounding dosing.ObjectivesAn anti- factor IIa (FIIa) UFH assay was evaluated for clinical use.MethodsThe BIOPHEN ANTI- IIa (Aniara Diagnostica) assay and anti- FXa INNOVANCE Heparin assay (Siemens Healthcare Diagnostics Products GmbH) were compared on the Siemens BCS XP system. Samples included UFH controls and calibrators and specimens from patients transitioning from apixaban or rivaroxaban to UFH. Method comparison, linearity, recovery, precision, and interference by direct FXa inhibitors were evaluated. The effect of the BIOPHEN ANTI- IIa assay on the rate of critically high UFH results was retrospectively reviewed 4 months after implementation.ResultsAccuracy studies using 0.24 and 0.50 IU/mL UFH yielded means and standard deviations of 0.26 ± 0.01 and 0.58 ± 0.01 IU/mL, respectively. Within- run and between- run coefficients of variation were 4.6% and 15.5% for the low control, and 1.8% and 10.6% for the high control. The method comparison slope was 0.9965 (r2 = 0.9468). The linear range was 0.1 to 1.3 IU/mL. The assay measured UFH in the presence of 192 ng/mL apixaban or 158 ng/mL rivaroxaban. Introduction of the assay for clinical use reduced the monthly percentage of critically high results from 9.4% to 3.8% for admitted heparinized patients who recently discontinued apixaban or rivaroxaban.ConclusionsThe BIOPHEN ANTI- IIa assay is suitable for patients transitioning off apixaban or rivaroxaban. | |
dc.publisher | Siemens Healthcare Diagnostics Products GmbH | |
dc.publisher | Wiley Periodicals, Inc. | |
dc.subject.other | rivaroxaban | |
dc.subject.other | heparin | |
dc.subject.other | factor IIa | |
dc.subject.other | drug monitoring | |
dc.subject.other | apixaban | |
dc.title | Anti- factor IIa (FIIa) heparin assay for patients on direct factor Xa (FXa) inhibitors | |
dc.type | Article | |
dc.rights.robots | IndexNoFollow | |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | |
dc.subject.hlbtoplevel | Health Sciences | |
dc.description.peerreviewed | Peer Reviewed | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/156142/2/jth14806.pdf | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/156142/1/jth14806_am.pdf | en_US |
dc.identifier.doi | 10.1111/jth.14806 | |
dc.identifier.source | Journal of Thrombosis and Haemostasis | |
dc.identifier.citedreference | Maclean PS, Tait RC. Hereditary and acquired antithrombin deficiency: epidemiology, pathogenesis and treatment options. Drugs. 2007; 67: 1429 - 1440. | |
dc.identifier.citedreference | Lippi G, Mattiuzzi C, Cervellin G, Favaloro EJ. Direct oral anticoagulants: analysis of worldwide use and popularity using Google Trends. Ann Transl Med. 2017; 5: 322. | |
dc.identifier.citedreference | BIOPHEN- ¢ ANTI- IIa (2 Stages Heparin Assay) [package insert]. Neuville- sur- Oise, France: HYPHEN BioMed; 2017. | |
dc.identifier.citedreference | INNOVANCE® Heparin Assay [package insert]. Marburg, Germany: Siemens Healthcare Diagnostics Products GmbH; 2017. | |
dc.identifier.citedreference | Macedo KA, Tatarian P, Eugenio KR. Influence of direct oral anticoagulants on anti- Factor Xa measurements utilized for monitoring heparin. Ann Pharmacother. 2018; 52: 154 - 159. | |
dc.identifier.citedreference | Douxfils J, Ageno W, Samama CM, et al. laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians. J Thromb Haemost. 2018; 16: 209 - 219. | |
dc.identifier.citedreference | Mani H. Interpretation of coagulation test results under direct oral anticoagulants. Int J Lab Hematol. 2014; 36: 261 - 268. | |
dc.identifier.citedreference | Chaudhary R, Sharma T, Garg J, et al. Direct oral anticoagulants: a review on the current role and scope of reversal agents. J Thromb Thrombolysis. 2020; 49: 271 - 286. | |
dc.identifier.citedreference | Hanslik A, Kitzmuller E, Tran US, et al. Anti- activated factor II assay for monitoring unfractionated heparin in children: results of the HEARTCAT study. J Thromb Haemost. 2017; 15: 38 - 46. | |
dc.identifier.citedreference | Exner T, Ahuja M, Ellwood L. Effect of an activated charcoal product (DOAC Stop- ¢) intended for extracting DOACs on various other APTT- prolonging anticoagulants. Clin Chem Lab Med. 2019; 57: 690 - 696. | |
dc.identifier.citedreference | Hanauer DA, Mei Q, Law J, Khanna R, Zheng K. Supporting information retrieval from electronic health records: a report of University of Michigan’s nine- year experience in developing and using the Electronic Medical Record Search Engine (EMERSE). J Biomed Inform. 2015; 55: 290 - 300. | |
dc.identifier.citedreference | BIOPHEN- ¢ UFH Control Plasma [package insert]. Neuville- sur- Oise, France: HYPHEN BioMed; 2018. | |
dc.identifier.citedreference | Application Guide for the UFH/LMWH assay with BIOPHEN- ¢ Anti- IIa (2 stages Heparin assay) (220005). Neuville- sur- Oise, France: HYPHEN BioMed; 2017. | |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.